HEALWELL and WELL Health Announce Competition Bureau has Concluded Its Merger Review and Issued a No Action Letter

Regulatory review clears WELL's control of HEALWELL; 5 million annual patient visits supported.

What the company is saying

HEALWELL AI Inc. and WELL Health Technologies Corp. announce that the Competition Bureau has concluded its review of WELL's acquisition of a controlling interest in HEALWELL, issuing a No Action Letter on October 22, 2026. The companies emphasize their cooperation with the Bureau, including compliance with a Federal Court order for records in December 2025. Hamed Shahbazi, Chairman of HEALWELL, highlights satisfaction with the regulatory outcome and reiterates a focus on executing strategy and delivering value to practitioners, patients, and shareholders. The announcement frames WELL as Canada's largest outpatient healthcare company, operating 275 clinics and supporting over 5 million annual patient visits. The tone is factual and positive, with forward-looking statements limited to ongoing strategic execution. No specific financial performance or integration metrics are disclosed.

What the data suggests

The announcement confirms that the Competition Bureau has closed its review of WELL's acquisition of a controlling stake in HEALWELL, with no further regulatory action planned as of October 22, 2026. WELL completed the acquisition on April 1, 2025, and the review included a Federal Court order for document production in December 2025. WELL operates 275 clinics in Canada and supports more than 5 million annual patient visits, indicating significant operational scale. The disclosure is limited to regulatory milestones, executive roles, and operational footprint, without providing financial figures, integration progress, or performance trends post-acquisition. Claims of market leadership and strategic execution are not substantiated by comparative or forward-looking data. The facts presented are clear and verifiable, but do not enable assessment of financial trajectory or synergy realization.

Analysis

The announcement is primarily a factual regulatory update, confirming the conclusion of the Competition Bureau's review and the issuance of a No Action Letter regarding WELL's acquisition of HEALWELL. The only forward-looking language is a generic statement about remaining focused on strategy and delivering value, which is not paired with any specific projections or exaggerated claims. All other key claims are realised and supported by dated regulatory and operational facts, such as the completion of the acquisition, the number of clinics, and annual patient visits. There is no promotional inflation of future benefits or overstatement of synergies, and no new capital outlay is disclosed in this update. The tone is positive but proportionate to the regulatory milestone achieved. The absence of financial metrics is not a deficiency here, as the release is not positioned as a financial or operational results update.

Risk flags

• ●The absence of post-acquisition financial or operational integration data means investors cannot assess whether the transaction has delivered tangible benefits or synergies, leaving a gap in evaluating the deal's success.
• ●Claims of market leadership and scale are not supported by comparative or historical data, which may overstate competitive positioning without additional evidence.
• ●While regulatory risk is now resolved, ongoing execution risk remains regarding the integration of HEALWELL and Orion Health into WELL's broader platform, especially given the scale of 275 clinics and 5 million annual patient visits.

Bottom line

This announcement removes regulatory uncertainty around WELL's controlling acquisition of HEALWELL, confirming that the Competition Bureau will not challenge the deal. WELL's operational scale—275 clinics and over 5 million annual patient visits—underscores its footprint in Canadian healthcare, but the release does not provide financial or integration performance data. Investors now have clarity on the legal status of the transaction, but lack visibility into whether the acquisition is delivering the expected value or synergies. The most actionable takeaway is that regulatory risk is resolved; the next critical disclosure should address operational and financial outcomes post-acquisition. Until such data is provided, the investment case rests on scale and strategic narrative rather than demonstrated results.

Announcement summary

(TSX:AIDX) HEALWELL AI Inc. and (TSX:WELL) WELL Health Technologies Corp. announced that the Commissioner of Competition has concluded the Competition Bureau's review of WELL's acquisition of a majority interest in HEALWELL and has issued a No Action Letter. The No Action Letter was issued on October 22, 2026, confirming that the Commissioner does not, at this time, intend to make an application under section 92 of the Competition Act regarding WELL's acquisition of a controlling interest in HEALWELL, which was completed on April 1, 2025, including HEALWELL's concurrent acquisition of Orion Health. In December 2025, the Bureau announced that it had obtained a Federal Court order for the production of records and information relating to the Transaction. HEALWELL and WELL cooperated with the Bureau throughout its review and produced the records and information requested. Hamed Shahbazi, Chairman of HEALWELL, stated that the company is pleased with the conclusion of the review and the issuance of the No Action Letter, and that HEALWELL remains focused on executing its strategy and delivering value to healthcare practitioners, patients, and shareholders. James Lee is the Chief Executive Officer of HEALWELL AI Inc. HEALWELL AI is a healthcare artificial intelligence company focused on preventative care, developing and acquiring technology and clinical science capabilities, including data science, AI-powered patient identification, and clinical decision support. HEALWELL is publicly traded on the Toronto Stock Exchange under the symbol "AIDX" and on the OTC Exchange under the symbol "HWAIF". WELL Health Technologies Corp. is Canada's largest outpatient healthcare company and a leading provider of technology-enabled healthcare solutions. WELL owns and operates 275 clinics in Canada, supporting more than 5 million annual patient visits. WELL provides electronic medical records, AI-powered clinical tools, patient engagement platforms, IT management services, and cybersecurity services through its subsidiaries WELLSTAR and CYBERWELL. WELL is publicly traded on the TSX under the symbol "WELL" and on the OTC Exchange under the symbol "WHTCF".

Disagree with this article?